SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Intel Trader who wrote (5112)8/12/1998 8:31:00 AM
From: margie   of 6136
 
Yeah!! Agouron's Viracept Receives Marketing Approval in Canada.
August 12. the Notice of Com;iancd allows Agouron to market Viracept in Canada for the treatment of HIV infecton in combination with reverse transcriptase inhibitors. the indication is based on analyses of surrogate endpoints in clinical studies up to 48 weeks.
Viracept is the first protease inhibitor to receive simultaneous approval of an indication for both adults and children in Canada.
Viracept has been available in Canada without charge since May 1997 ...HIV infected children aged two to 12 with no alternatives have received the drug through the Emergency Drug Release Program.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News